Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Swedish Orphan Biovitrum: Clinical Trials & FDA Approval Profile

Swedish Orphan Biovitrum (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (1 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.6%
Median Closed Enrollment vs National (145 pts)16 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Swedish Orphan Biovitrum
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)4 (1)
Completed vs Stopped Early10 / 3 (17.6%)
Median Closed Actual Enrollment16 participants
Physical Hospital Site Disclosure85.7% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Swedish Orphan Biovitrum
Hospital Research SiteLocationShared Protocols
Fukushima Medical University HospitalFukushima3
MD Anderson Cancer CenterHouston, TX2
Mayo Clinic RochesterRochester, MN2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Swedish Orphan Biovitrum
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06782373A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Phase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Swedish Orphan Biovitrum Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI